Company intelligence / Profile preview

Dermis Pharma

Bornova, İzmir, Turkeydermispharma.com ↗
Ownership
Private
Development stage
Other
01

Overview

Dermalix, the lead product, is a bioactive wound dressing that accelerates healing of diabetic wounds and bedsores. It has received CE certification for meeting EU health, safety, and environmental standards. The product is commercially available in Turkey since June 2021. Clinical results support its efficacy in promoting tissue repair[3].

Therapeutic areas
DermatologyEndocrinology
Modalities
DeviceNanoparticle
Industry
Consumable Medical Devices
02

Partnerships

Abdi İbrahim

Beyond the preview

Go deeper on Dermis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermis Pharma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call